Clinical Trial Update: Study of Efficacy and Safety of CTL019 in Adult ALL Patients [Phase 2]

View source ↗

Summary

A Phase 2 study examining CTL019 (tisagenlecleucel) in adults with B-cell acute lymphoblastic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CTL019 (tisagenlecleucel) (tisagenlecleucel)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: WITHDRAWN